Heterogeneous expression of 36 AML markers in a large AML patient cohort. (A) MFI of PM markers in CD34⁺cells, or CD34^-CD117⁺ cells for NPM1cyt, AML patients (n = 84) vs healthy controls (NBM, n = 7; mobilized peripheral blood stem cells, n = 2). P values were corrected for multiple testing by using the FDR method. Significant differences compared with NBM are indicated: *P < .05, **P < .01, ***P < .001. (B) Expression of markers compared with healthy controls with a significant shift in MFI (≥2-fold increase in MFI) shown in red. Not determined markers are shown in gray. Markers were ranked according to the amount of positive AMLs.